NG Biotech announces FDA approval for diagnostic assays

​NG Biotech and Hardy Diagnostics have received the US FDA breakthrough device designation for two rapid diagnostic assays, NG-TEST Candida auris and NG-TEST Acineto-5 targeting critical drug-resistant pathogens.

The post NG Biotech announces FDA approval for diagnostic assays appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

MSD and Mayo Clinic team up to advance AI in drug development
Portal Diabetes’ insulin pump receives FDA breakthrough device designation 
Janux commences participant dosing in Phase I JANX011 trial
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
VB Spine to acquire xvision Spine System from Augmedics

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us